{
    "nct_id": "NCT06392711",
    "official_title": "UW23129: a Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients with Medical Xerostomia",
    "inclusion_criteria": "* Xerostomia, defined as an unstimulated salivary flow of less than or equal to 0.5 mL in 5 minutes\n* Xerostomia not resulting from radiotherapy (medical xerostomia) defined as an unstimulated salivary flow ≤0.5 mL/5 minutes documented at any time following Xerostomia diagnosis and prior to enrollment.\n* ≥ 18 years of age, ≤ 90 years of age\n* Karnofsky performance status ≥ 70, patient eligible for bone marrow aspirate with wakeful anesthesia\n* Willing and able to give informed consent\n* Radiographically confirmed bilateral submandibular glands\n* If female of childbearing potential, negative pregnancy test\n* Males and females of childbearing potential willing to use acceptable contraception\n* Laboratory Values (within 42 calendar days of enrollment):\n\n  * Hgb ≥ 9 g/dL (5.58 mmol/L)\n  * Platelets ≥ 100,000/µL\n  * ANC ≥ 1000/µL\n  * Lymphocytes ≥ 800/µL\n  * PT/INR and PTT within normal limits based on age/sex\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "* Patients with one submandibular gland\n* Sialolithiasis\n* Poorly-controlled diabetes mellitus (HBA1c ≥ 7%)\n* Patients who initiated any diuretic therapy before developing dry mouth symptoms or ESRD\n* Untreated oral candidiasis based on physical exam at enrollment\n* Malignancy within the last 2 years (except adequately treated stage I lung cancer, low risk prostate cancer that has been treated or is undergoing active surveillance, adequately treated non-melanoma skin cancer, adequately treated DCIS, or adequately treated stage I cervical cancer)\n* For patients on immunosuppressive therapy, must be on stable dose of immunosuppressive therapy for at least 2 months, allowing for dose adjustments for blood levels of drugs\n* Transfusion dependency\n* Life expectancy ≤ 6 months as determined by the investigator\n* Use of investigational drugs, biologics, or devices within 30 calendar days prior to enrollment\n* Pregnant or lactating women or those who plan to become pregnant during the study\n* Not suitable for study participation due to other reasons at discretion of investigators.\n* Enrollment in another clinical study possibly interfering with the endpoints of this study",
    "miscellaneous_criteria": ""
}